# MagnetisMM-2 (NCT04798586)

> MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04798586
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Relapsed or Refractory Multiple Myeloma
- Interventions: Elranatamab (PF-06863135)
- Enrollment: 4
- Primary outcome: Number of Participants With Dose Limiting Toxicities (DLTs)

## Indexed commentary on MagnetisMM-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=magnetismm-2-nct04798586